{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"13.8","value":"4.3"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"2.1","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"PFS was defined as the time from the first dose to the first documented PD or death due to any cause, whichever occurs first. PD is the appearance of any new lesion or increase by ≥ 50% of previously involved site from nadir. Calculated from the product-limit (Kaplan-Meier) method for censored data.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)"},{"description":"Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG001","title":"Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants who received at least one dose of study medication (pembrolizumab).","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months (Database Cutoff Date: 28MAY2019)","title":"Progression Free Survival (PFS) Based on IWG Response Assessment Criteria by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}